These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18482099)

  • 1. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.
    Emond P; Guilloteau D; Chalon S
    CNS Neurosci Ther; 2008; 14(1):47-64. PubMed ID: 18482099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
    Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
    J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.
    Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1220-30. PubMed ID: 12811422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
    Chalon S; Hall H; Saba W; Garreau L; Dollé F; Halldin C; Emond P; Bottlaender M; Deloye JB; Helfenbein J; Madelmont JC; Bodard S; Mincheva Z; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 2006 Apr; 317(1):147-52. PubMed ID: 16339913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
    Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
    Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
    Ziebell M
    Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
    Guilloteau D; Emond P; Baulieu JL; Garreau L; Frangin Y; Pourcelot L; Mauclaire L; Besnard JC; Chalon S
    Nucl Med Biol; 1998 May; 25(4):331-7. PubMed ID: 9639293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers.
    Ribeiro MJ; Ricard M; Lièvre MA; Bourgeois S; Emond P; Gervais P; Dollé F; Syrota A
    Nucl Med Biol; 2007 May; 34(4):465-70. PubMed ID: 17499737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
    Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard J; Farde L; Sedvall G
    Neuroimage; 1999 Jan; 9(1):108-16. PubMed ID: 9918732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter.
    Chalon S; Garreau L; Emond P; Zimmer L; Vilar MP; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 1999 Nov; 291(2):648-54. PubMed ID: 10525084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments.
    Stepanov V; Schou M; Järv J; Halldin C
    Appl Radiat Isot; 2007 Mar; 65(3):293-300. PubMed ID: 17081763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
    Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat.
    Barc S; Page G; Barrier L; Garreau L; Guilloteau D; Fauconneau B; Chalon S
    J Neurochem; 2002 Feb; 80(3):365-74. PubMed ID: 11905985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.